Static Chart Qurient Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
4,320 ^KRW	+19.01%		+26.50%	-7.49%

May. 21	Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	CI
May. 17	Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI

Duration

Period